Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.32 |
| ▸ | MAPK13 | O15264 | 7/20 | 0.32 |
| ▸ | MAPK12 | P53778 | 6/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 6/20 | 0.32 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2079230 | 1.00 | CDK8 (0.33) | CDK8TRPV1MAPK14MAPK13MAPK12 | |
| SCHEMBL2081646 | 0.79 | MAPK14 (0.58) | MAPK14MAPK11ABL1 | |
| Hydrochloric Acid SCHEMBL2082291 | 0.79 | NR1H2 (0.37) | — | |
| SCHEMBL2080666 | 0.78 | PTPN1 (0.31) | CDK8TRPV1 | |
| SCHEMBL2080663 | 0.78 | NR1H2 (0.36) | CDK8TRPV1MAPK14MAPK13MAPK12 | |
| SCHEMBL2081496 | 0.76 | PTPN1 (0.42) | CDK8TRPV1MAPK14MAPK13MAPK12 | |
| SCHEMBL2081497 | 0.76 | PTPN1 (0.42) | CDK8TRPV1MAPK14MAPK13MAPK12 | |
| SCHEMBL2083770 | 0.74 | PDE4B (0.38) | CDK8TRPV1MAPK14MAPK13MAPK12 | |
| SCHEMBL2083767 | 0.74 | PDE4B (0.38) | CDK8TRPV1MAPK14MAPK13MAPK12 | |
| SCHEMBL2083902 | 0.70 | CA12 (0.53) | CDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | CDK8 291/4885TRPV1 2872/4885MAPK14 128/4885 |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | CDK8 241/4885TRPV1 2537/4885MAPK14 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.